Rein Therapeutics, Inc.
RNTX evidence brief
What we can confirm
- BioSniper Score:
- 7.9 / 10
- Market Cap:
- $67.7M
- Lead Asset:
- lti-01 (Phase 2)
What it means
What to watch
Prepared research question
What matters most for RNTX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · RNTX
Rein Therapeutics (RNTX) is a clinical-stage biopharmaceutical company developing novel therapies for orphan pulmonary and fibrosis indications, with its lead candidate LTI-03 in a global Phase 2 trial for idiopathic pulmonary fibrosis (IPF).
Key risk: Cash runway limited
BioSniper Score
Based on 4 of 6 signals
Market Cap
$67.7M
Cash Runway
—
Lead Asset
lti-01 (Phase 2)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 3 pipeline candidates · 2 clinical trials for Rein Therapeutics, Inc..
Rein Therapeutics (RNTX) is a clinical-stage biopharmaceutical company developing novel therapies for orphan pulmonary and fibrosis indications, with its lead candidate LTI-03 in a global Phase 2 trial for idiopathic pulmonary fibrosis (IPF).
- Lead candidate LTI-03 is a peptide in a Phase 2 RENEW trial for IPF; the company surpassed 25% enrollment and expects interim data in the second half of 2026 [news · 2026-08-14].
- Cash & equivalents were $8.5M as of 2026-06-30, with zero revenue and a net loss of $6.4M for the quarter [sec].
- Completed an oversubscribed $57.5 million public offering in 2026 [news · 2026-08-14].
- Development of LTI-01 and preclinical candidates has been suspended indefinitely due to capital limitations [sec_mda · as of 2026-03-26].
- The company has never generated revenue from product sales or an operating profit [sec_mda · as of 2026-03-26].
What works
- LTI-03 has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling in a Phase 1b trial [sec_mda · as of 2026-08-14].
- The Phase 2 RENEW trial is enrolling globally across five countries, with initial topline data expected in 2H 2026 [news · 2026-07-21].
- The company successfully raised $57.5 million in an oversubscribed public offering, supported by healthcare-focused investors [news · 2026-08-14].
What to weigh
- The company has no approved products and has never generated revenue from product sales [sec_mda · as of 2026-03-26].
- Cash reserves are limited ($8.5M as of 2026-06-30) relative to ongoing clinical trial costs [sec].
- Development of LTI-01 and all preclinical candidates has been suspended indefinitely due to capital constraints [sec_mda · as of 2026-03-26].
- The company has incurred significant operating losses and negative cash flows from operations since inception [sec_mda · as of 2025-08-14].
From the filings
Quoted directly from source documents.
LTI-03 is the lead product candidate in clinical development for IPF.
“We currently have one lead product candidate in clinical development, LTI-03.”
SEC MD&A · August 14, 2026
The Phase 2 RENEW trial surpassed 25% enrollment and interim data is expected in 2H 2026.
“Surpassed 25% enrollment milestone in the Global Phase 2 RENEW trial evaluating LTI-03 in idiopathic pulmonary fibrosis (IPF); on track to report interim data in the second half of 2026”
News · August 14, 2026
LTI-01 development has been suspended due to capital limitations.
“current capital limitations, we have suspended development activities for LTI-01 and our candidates in preclinical development focused on fibrosis indications for an indefinite period”
SEC MD&A · March 26, 2026
The company has never generated revenue from product sales.
“Since inception, we have not generated any revenue from product sales and have incurred significant operating losses and negative cash flows from operations.”
SEC MD&A · August 14, 2025
Catalyst timeline
- 2026-02-02 · Phase 2 RENEW trial start — A Phase 2, randomized, double-blind, placebo-controlled study of LTI-03 in IPF patients began enrollment.
- 2023-07-06 · Phase 1 start — A Phase 1 dose-escalation study of LTI-03 in treatment-naïve IPF subjects was initiated.
Risks & what to watch (4)›
Key risks
- Cash runway limited — Cash of $8.5M as of 2026-06-30 may not sustain operations through Phase 2 completion without further financing [sec].
- Single-asset dependency — All resources are allocated to LTI-03; other pipeline programs are suspended indefinitely [sec_mda · as of 2026-03-26].
- No revenue or profit history — Company has never generated product revenue or operating profit [sec_mda · as of 2026-03-26].
- Clinical trial execution risk — Phase 2 RENEW trial is ongoing; failure to meet endpoints would be a major setback [news · 2026-08-14].
What to watch
- Interim topline data from the Phase 2 RENEW trial expected in the second half of 2026 [news · 2026-08-14].
- Cash burn rate and potential need for additional financing given $8.5M cash as of 2026-06-30 [sec].
- Any updates on the resumption of LTI-01 or preclinical programs [sec_mda · as of 2026-03-26].
- Regulatory developments or partnership announcements that could extend cash runway [sec_mda · as of 2026-08-14].
Sources: Catalysts · News · SEC MD&A · Generated September 26, 2026 · How we verify sources →
Run Rein Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Rein Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.20 · 0% dilution
Lead: Phase 2
3 candidates
No upcoming catalysts tracked
5 buys · 0 sells (180d)
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
46
Total value held
$14.8M
| Holder | Shares | Value |
|---|---|---|
| voss capital, lp | 4,388,362 | $5.7M |
| bios capital management, lp | 1,982,375 | $2.6M |
| vanguard capital management llc | 998,521 | $1.3M |
| university of texas/texas am investment management co | 511,610 | $665K |
| cable car capital, lp | 420,000 | $546K |
| prosight management, lp | 411,600 | $535K |
| sigma planning corp | 348,677 | $453K |
| geode capital management, llc | 344,690 | $448K |
| texas capital bank wealth management services inc | 273,625 | $356K |
| gagnon securities llc | 239,520 | $311K |
Showing top 10 of 46 institutional holders of Rein Therapeutics, Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 21, 2026- % of float
- 1.7%
- Days to cover
- 5.4
- Shares short
- 487,162
- Daily short volume (Oct 12, 2026)
- 24.3%
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
RNTX short interestGovernance
Frequently asked questions
What is the AI investment thesis for Rein Therapeutics, Inc.?
Rein Therapeutics (RNTX) is a clinical-stage biopharmaceutical company developing novel therapies for orphan pulmonary and fibrosis indications, with its lead candidate LTI-03 in a global Phase 2 trial for idiopathic pulmonary fibrosis (IPF).
What is Rein Therapeutics, Inc.'s lead drug candidate?
Rein Therapeutics, Inc.'s most advanced tracked candidate is lti-01 (Phase 2) for Loculated pleural effusion (LPE).
Who is the CEO of Rein Therapeutics, Inc.?
Dr. James Brian Windsor Ph.D. is the chief executive officer of Rein Therapeutics, Inc. (RNTX).
Where is Rein Therapeutics, Inc. headquartered?
Rein Therapeutics, Inc. (RNTX) is headquartered in Austin, TX, United States.
What therapeutic areas does Rein Therapeutics, Inc. focus on?
Rein Therapeutics, Inc. develops therapies across Rare Disease, Respiratory.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.